Oct 1 (Reuters) – Eli Lilly and Company: * LILLY'S ORAL GLP-1, FOUNDAYO (ORFORGLIPRON), DEMONSTRATED CARDIOVASCULAR SAFETY ALONGSIDE SUSTAINED A1C REDUCTION AND WEIGHT LOSS IN ITS LARGEST AND LONGEST
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
By Chuck Mikolajczak and Shashwat Chauhan NEW YORK, Sept 30 (Reuters) - Nasdaq climbed on…
Man City need siege mentality after rules breach verdict, psychotherapist says
VIDEO SHOWS: REUTERS INTERVIEW WITH SPORTS PSYCHOTHERAPIST STEVE POPE COMPLETE SHOTLIST AND SCRIPT TO FOLLOW…
UPDATE 1-Australia's Transurban to acquire CPPIB interests in Sydney toll roads for $3.13 billion
(Updates with further details and context throughout) Oct 1 (Reuters) - Australian toll road operator…
